| Literature DB >> 23741479 |
Olena Zakharchenko1, Monica Cojoc, Anna Dubrovska, Serhiy Souchelnytskyi.
Abstract
Transforming growth factor-β (TGFβ) is a potent regulator of tumorigenesis, although mechanisms defining its tumor suppressing and tumor promoting activities are not understood. Here we describe phosphoproteome profiling of TGFβ signaling in mammary epithelial cells, and show that 60 identified TGFβ-regulated phosphoproteins form a network with scale-free characteristics. The network highlighted interactions, which may distribute signaling inputs to regulation of cell proliferation, metabolism, differentiation and cell organization. In this report, we identified two novel and TGFβ-dependent phosphorylation sites of 14-3-3σ, i.e. Ser69 and Ser74. We observed that 14-3-3σ phosphorylation is a feed-forward mechanism in TGFβ/Smad3-dependent transcription. TGFβ-dependent 14-3-3σ phosphorylation may provide a scaffold for the formation of the protein complexes which include Smad3 and p53 at the Smad3-specific CAGA element. Furthermore, breast tumor xenograft studies in mice and radiobiological assays showed that phosphorylation of 14-3-3σ at Ser69 and Ser74 is involved in regulation of cancer progenitor population and radioresistance in breast cancer MCF7 cells. Our data suggest that TGFβ-dependent phosphorylation of 14-3-3σ orchestrates a functional interaction of TGFβ/Smad3 with p53, plays a role in the maintenance of cancer stem cells and could provide a new potential target for intervention in breast cancer.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23741479 PMCID: PMC3669286 DOI: 10.1371/journal.pone.0065163
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Outline of the experimental workflow for phosphoproteome profiling of TGFβ1 signaling.
Proteins identified as changing their phosphorylation upon TGFβ1 treatment.
| No | Protein Identity | Accesion No. | Probability | Est'd Z | Sequence coverage, % | Theoretical value | Experimental value | Matched peptides | ||
| pI | Mr(kDa) | pI | Mr(kDa) | |||||||
| 1 | Heat shock 70 kDa protein 8 isoform 2 | NP_69488.1 | 1.0e+000 | 2.16 | 36 | 5.6 | 53.61 | 4.8 | 60 | 15 |
| 2 | Heat shock 70 kDa protein 9B (mortalin-2) | AAH30634.1 | 1.0e+000 | 2.28 | 34 | 6.0 | 74.12 | 5.0 | 60 | 21 |
| 3 | Mitosis-specific chromosome segregation protein SMC1 homolog | AAB34405.1 | 1.0e+000 | 2.28 | 18 | 7.6 | 143.81 | 6.5 | 47.5 | 17 |
| 4 | Keratin 14 | AAP35850.1 | 1.0e+000 | 2.39 | 38 | 5.1 | 51.92 | 4.8 | 47 | 27 |
| 5 | ENO-1 | AAH50642.1 | 1.0e+000 | 1.98 | 35 | 7.0 | 47.49 | 7.5 | 45 | 13 |
| 6 | ENO-1 | AAH50642.1 | 1.0e+000 | 2.15 | 42 | 7.0 | 47.49 | 7.4 | 45 | 18 |
| 7 | Eukaryotic translation initiation factor 3, subunit 5 epsilon (EIF3S5) | AAP35540.1 | 1.0e+000 | 1.97 | 27 | 5.2 | 37.13 | 4.7 | 37 | 10 |
| 8 | ENO-1 | AAH50642.1 | 1.0e+000 | 2.08 | 49 | 7.0 | 47.49 | 7.3 | 45 | 19 |
| 9 | Keratin 5 | AAH71906.1 | 9.6e−001 | 1.45 | 24 | 7.7 | 62.59 | 7.8 | 40 | 15 |
| 10 | A+U-rich element RNA binding factor | BAA22860.1 | 1.0e+000 | 2.43 | 29 | 8.9 | 30.34 | 7.0 | 32 | 10 |
| 11 | Annexin A2, isoform 2 | AAH23990.1 | 1.0e+000 | 2.30 | 35 | 7.7 | 38.79 | 7.2 | 32 | 15 |
| 12 | CNN2 (calponin 2) | CAG46609.1 | 1.0e+000 | 1.04 | 24 | 7.0 | 34.09 | 7.0 | 32 | 10 |
| 13 | Keratin 10 | AAA59199.1 | 1.0e+000 | 1.70 | 18 | 4.7 | 39.84 | 8.0 | 26 | 9 |
| 14 | Peroxiredoxin 6 | NP_004896.1 | 1.0e+000 | 1.44 | 37 | 6.0 | 25.13 | 6.5 | 25 | 8 |
| 15 | Peroxiredoxin 1 | CAI13096.1 | 1.0e+000 | 2.26 | 44 | 6.4 | 19.13 | 9.0 | 19 | 10 |
| 16 | Keratin 14 | NP_000517.2 | 1.0e+000 | 2.35 | 40 | 5.1 | 51.89 | 4.6 | 45 | 26 |
| 17 | Keratin 17 | NP_000413.1 | 1.0e+000 | 2.32 | 39 | 5.0 | 49.37 | 4.3 | 40 | 23 |
| 18 | Laminin-binding protein | CAA43469.1 | 9.7e−001 | 0.69 | 20 | 4.8 | 31.89 | 4.0 | 33 | 6 |
| 19 | RAB6-interacting protein 2 (RAB6IP2) | AAH68006.1 | 9.4e−001 | 0.61 | 19 | 6.8 | 71.88 | 4.8 | 33 | 14 |
| 20 | Eukaryotic translation initiation factor 3, subunit 2 beta (EIF3S2) | NP_003748.1 | 1.0e+000 | 2.22 | 25 | 5.4 | 36.88 | 5.2 | 33 | 14 |
| 21 | Radical S-adenosyl methionine and flavodoxin domains 1 (RSAFD1) | AAH51888.1 | 9.9e−001 | 0.70 | 17 | 5.8 | 44.08 | 5.0 | 32 | 8 |
| 22 | Eukaryotic translation initiation factor 3, subunit 2 beta (EIF3S2) | NP_003748.1 | 1.0e+000 | 1.68 | 39 | 5.4 | 36.88 | 4.2 | 32 | 13 |
| 23 | Keratin 10, typeI, cytoskeletal | KRHU0 | 1.0e+000 | 1.87 | 26 | 5.2 | 59.74 | 5.2 | 26 | 17 |
| 24 | Zinc finger protein 62 homolog | NP_689496.1 | 1.0e+000 | 0.86 | 16 | 9.9 | 58.78 | 8.3 | 20 | 9 |
| 25 | RAB6-interacting protein 2 isoform alpha | NP_055879.1 | 6.3e−001 | 0.74 | 15 | 6.2 | 108.89 | 8.3 | 20 | 14 |
| 26 | Antigen MLAA-34 | AAQ93064.1 | 9.0e−001 | 0.93 | 26 | 8.7 | 39.24 | 8.0 | 18 | 8 |
| 27 | Eukaryotic translation initiation factor 4H, isoform 2 | AAH10021.1 | 1.0e+000 | 2.19 | 44 | 7.8 | 25.24 | 8.0 | 25 | 9 |
| 28 | Keratin 10, type I, cytoskeletal | KRHU0 | 1.0e+000 | 1.78 | 22 | 5.2 | 59.74 | 9.5 | 20 | 12 |
| 29 | Heterogeneous nuclear ribonucleoprotein A2/B1 isoform A2 | NP_002128.1 | 1.0e+000 | 1.84 | 20 | 8.7 | 36.05 | 9.2 | 30 | 8 |
| 30 | Heterogeneous nuclear ribonucleoprotein A2/B1 isoform A2 | NP_002128.1 | 1.0e+000 | 2.36 | 48 | 8.7 | 36.05 | 9.3 | 30 | 13 |
| 31 | Heterogeneous nuclear ribonucleoprotein A2/B1 isoform A2 | NP_002128.1 | 1.0e+000 | 2.18 | 40 | 8.7 | 36.05 | 9.0 | 32 | 15 |
| 32 | Heterogeneous nuclear ribonucleoprotein A2/B1 isoform A2 | NP_002128.1 | 1.0e+000 | 2.31 | 29 | 8.7 | 36.05 | 9.2 | 29 | 11 |
| 33 | Heterogeneous nuclear ribonucleoprotein A2/B1 isoform A2 | NP_002128.1 | 1.0e+000 | 2.38 | 42 | 8.7 | 36.05 | 8.7 | 28 | 12 |
| 34 | Heterogeneous nuclear ribonucleoprotein A2/B1 isoform A2 | NP_002128.1 | 1.0e+000 | 1.09 | 15 | 8.7 | 36.05 | 8.7 | 25 | 7 |
| 35 | Human Muscle Fructose 1.6-Biphosphate Aldolase Complexed with Fructose 1,6-Biphosphate | 4ALD | 1.0e+000 | 2.09 | 28 | 8.8 | 39.73 | 8.8 | 35 | 10 |
| 36 | Human Muscle Fructose 1.6-Biphosphate Aldolase Complexed with Fructose 1,6-Biphosphate | 4ALD | 1.0e+000 | 2.25 | 24 | 8.8 | 39.73 | 9.1 | 35 | 9 |
| 37 | Human Muscle Fructose 1.6-Biphosphate Aldolase Complexed with Fructose 1,6-Biphosphate | 4ALD | 1.0e+000 | 1.28 | 22 | 8.8 | 39.73 | 9.0 | 35 | 8 |
| 38 | Vasodilator-stimulated phosphoprotein | CCA67147.2 | 1.0e+000 | 2.15 | 26 | 9.2 | 39.76 | 9.5 | 45 | 6 |
| 39 | Vasodilator-stimulated phosphoprotein | CCA67147.2 | 1.0e+000 | 1.77 | 21 | 9.2 | 39.76 | 9.3 | 45 | 11 |
| 40 | Keratin 10, type I, cytoskeletal | KRHU0 | 8.6e−001 | 0.60 | 13 | 5.2 | 59.74 | 7.2 | 46 | 8 |
| 41 | ENO 1 | AAH50642.1 | 1.0e+000 | 2.35 | 43 | 7.0 | 47.49 | 6.8 | 38 | 19 |
| 42 | ENO 1 | AAH50642.1 | 1.0e+000 | 2.40 | 35 | 7.0 | 47.49 | 7.0 | 38 | 14 |
| 43 | Inosine monophosphate (IMP) dehydrogenase 2 | AAH155567.1 | 9.7e−001 | 0.69 | 12 | 6.4 | 56.24 | 6.5 | 47 | 8 |
| 44 | DEAD (Asp-Glu-Ala-Asp) box polypeptide 48 | NP_055555.1 | 9.9e−001 | 0.79 | 20 | 6.3 | 47.25 | 6.3 | 47 | 7 |
| 45 | Stress-induced phosphoprotein 1 (Hsp70/Hsp90-organining protein) | AAV38814.1 | 1.0e+000 | 1.98 | 31 | 6.4 | 63.25 | 6.5 | 50 | 20 |
| 46 | Stress-induced phosphoprotein 1 (Hsp70/Hsp90-organining protein) | AAV38814.1 | 1.0e+000 | 1.98 | 33 | 6.4 | 63.25 | 6.7 | 50 | 20 |
| 47 | Fumarate hydratase | AAP88841.1 | 1.0e+000 | 1.32 | 17 | 9.0 | 54.79 | 7.5 | 40 | 9 |
| 48 | Kerain 10, type I, cytoskeletal 10 | K1CJ | 1.0e+000 | 1.14 | 13 | 5.1 | 59.73 | 7.2 | 40 | 9 |
| 49 | Zinc finger protein 62 homolog | NP_689496.1 | 9.7e−001 | 0.63 | 19 | 9.9 | 58.78 | 7.8 | 35 | 9 |
| 50 | Antigen MLAA-34 | AAQ93064.1 | 9.7e−001 | 0.61 | 18 | 8.7 | 39.24 | 6.8 | 30 | 6 |
| 51 | Cytokeratin 9 | AAC60619.1 | 1.0e+000 | 1.83 | 23 | 5.1 | 62.20 | 6.5 | 33 | 8 |
| 52 | RNA binding protein 4 | AAH32735.1 | 1.0e+000 | 1.94 | 23 | 6.6 | 40.70 | 6.6 | 33 | 9 |
| 53 | Keratin 9 | NP_000217.2 | 1.0e+000 | 2.18 | 26 | 5.1 | 62.27 | 6.9 | 33 | 14 |
| 54 | Qntigen MLAA-34 | AAQ93064.1 | 9.8e−001 | 0.68 | 23 | 8.7 | 39.24 | 7.3 | 27 | 6 |
| 55 | Zinc finger protein 62 homolog | NP_689496.1 | 1.0e+000 | 0.99 | 18 | 9.9 | 58.78 | 7.2 | 26 | 8 |
| 56 | Guanyl nucleotide releasing protein 4 | AAL87858.1 | 9.4e−001 | 0.51 | 9 | 9.1 | 76.22 | 7.5 | 27 | 9 |
| 57 | Transcription factor NRF | AAH47878.1 | 9.6e−001 | 0.57 | 11 | 9.2 | 78.34 | 7.9 | 28 | 7 |
| 58 | Heterogeneous nuclear ribonucleoprotein A2/B1 isoform A2 | NP_002128.1 | 1.0e+000 | 2.31 | 34 | 8.7 | 36.05 | 7.9 | 30 | 11 |
| 59 | Heat shock 70 kDa protein 9B (mortalin-2) | AAH30634.1 | 1.0e+000 | 2.26 | 41 | 6.0 | 74.12 | 5.0 | 48 | 25 |
| 60 | Heat shock 70 kDa protein 9B (mortalin-2) | AAH30634.1 | 1.0e+000 | 2.26 | 33 | 6.0 | 74.12 | 4.5 | 60 | 19 |
| 61 | Heat shock 70 kDa protein 9B precursor (MTHSP75) | AAA67526.1 | 1.0e+000 | 2.37 | 18 | 6.0 | 74.05 | 5.0 | 50 | 14 |
| 62 | Heat shock 70 kDa protein 9B (mortalin-2) | AAH30634.1 | 1.0e+000 | 1.71 | 17 | 6.0 | 74.12 | 5.3 | 50 | 11 |
| 63 | Unknown (chaperonin containing TCP1) | AAH02971.1 | 1.0e+000 | 1.99 | 23 | 5.4 | 59.91 | 5.2 | 47 | 12 |
| 64 | Prolyl 4-hydroxylase, beta subunit | NP_000909.2 | 1.0e+000 | 2.28 | 32 | 4.8 | 57.50 | 4.0 | 47 | 17 |
| 65 | Chaperonin containing TCP1, subunit 2 (beta) | AAI13517.1 | 1.0e+000 | 0.86 | 16 | 9.9 | 58.78 | 8.3 | 20 | 10 |
| 66 | Tubulin, beta polypeptide | NP_821133.1 | 1.0e+000 | 2.39 | 38 | 4.8 | 50.11 | 4.3 | 46 | 34 |
| 67 | Keratin 7 | NP_005547.2 | 1.0e+000 | 2.39 | 35 | 5.4 | 51.46 | 5.0 | 46 | 17 |
| 68 | Heterogeneous nuclear ribonucleoprotein K isoform a | NP_112553.1 | 1.0e+000 | 2.32 | 28 | 5.2 | 51.30 | 7.5 | 46 | 13 |
| 69 | Gamma-actin | JC5818 | 1.0e+000 | 1.80 | 35 | 5.3 | 41.99 | 5.0 | 35 | 10 |
| 70 | Ribosomal protein P0 | AAH01127.1 | 1.0e+000 | 1.98 | 34 | 5.4 | 34.43 | 5.3 | 31 | 10 |
| 71 | Ribosomal protein P0 | AAH01127.1 | 1.0e+000 | 1.98 | 34 | 5.4 | 34.43 | 5.5 | 31 | 9 |
| 72 | SFN (14-3-3 sigma, stratifin) | AAH01550.1 | 1.0e+000 | 2.18 | 37 | 4.8 | 24.38 | 6.5 | 32 | 10 |
| 73 | Eukaryotic translation elongation factor 1 beta 2 | AAP35742.1 | 1.0e+000 | 1.54 | 29 | 4.5 | 24.92 | 3.7 | 25 | 8 |
| 74 | SFN (14-3-3 sigma, stratifin) | AAH01550.1 | 1.0e+000 | 2.18 | 45 | 4.8 | 24.38 | 4.2 | 24 | 21 |
| 75 | Mitochondrial short-chain enoyl-coenzyme A hydratase 1 precursor | NP_004083.2 | 1.0e+000 | 2.29 | 50 | 8.9 | 31.81 | 6.0 | 24 | 16 |
| 76 | Proteasome alpha 5 subunit | NP_002781.2 | 1.0e+000 | 2.29 | 50 | 8.9 | 31.81 | 6.0 | 24 | 16 |
| 77 | Ribosomal protein S6 kinase, 90 kda, polypeptide 3 | BAC81131.1 | 1.0e+000 | 1.05 | 16 | 6.4 | 82.48 | 6.3 | 10 | 10 |
| 78 | Keratin9 | NP_00217.2 | 1.0e+000 | 1.14 | 18 | 5.1 | 62.27 | 9.0 | 10 | 14 |
| 79 | Chain B Human Mitochondrial Single Strand DNA Binding Protein (HMSSB) | 1S3O_B | 1.0e+000 | 1.98 | 49 | 8.2 | 15.18 | 9.2 | 8 | 7 |
| 80 | RAS guanyl releasing protein 4 | AAK85701.1 | 9.7e−001 | 0.63 | 11 | 9.0 | 11.79 | 9.0 | 7 | 10 |
| 81 | Fk506 Binding Protein Fkbp Mutant R42kH87V Complex With Immunosuppressant Fk506 | 1BKF_A | 1.0e+000 | 2.24 | 46 | 8.1 | 11.79 | 9.0 | 7 | 10 |
| 82 | Heat shock 70 kDa protein 8 isoform 1 | NP_006588.1 | 1.0e+000 | 2.37 | 32 | 5.4 | 71.11 | 4.1 | 63 | 19 |
| 83 | Eukaryotic translation elongation factor 2 | NP_001952.1 | 8.2e−001 | 0.64 | 13 | 6.4 | 96.29 | 3.9 | 25 | 11 |
| 84 | Endoplasmic reticulum protein 29 precursor | NP_006808.1 | 1.0e+000 | 2.26 | 34 | 6.8 | 29.03 | 6.2 | 25 | 10 |
| 85 | Lamin A/C isoform 2 | NP_005563.1 | 1.0e+000 | 2.31 | 35 | 6.4 | 65.17 | 6.6 | 49 | 18 |
)- selected phosphoprotein spots from 2-D gels;
)-NCBI sequence identification numbers.
Probability, Z-value, coverage and theoretical pI and Mr were obtained from ProFound search. The calculation of experimental pI and Mr was based on migration of proteins on 2-D gels.
Figure 214-3-3σ sub-network of TGFβ1-regulated phosphoproteins.
(A) Graphs show distribution of connections for species of the network. Distribution for proteins identified by phosphoproteomics (rhombs; experimental data) and as would be expected by a power law distribution of connections of species in an ideal scale-free network (squares; predicted distribution) are shown. (B) A sub-network of 14-3-3σ (SFN). Proteins which are in proximal dependencies to 14-3-3σ were extracted from the complete network (Figure S5) into the presented sub-network. (C) Signaling pathways involving the proteins assembled in the 14-3-3σ sub-network. The analysis was performed using Gene Set Analysis Toolkit V2 software. (D) Validation of 14-3-3σ phosphorylation upon treatment of cells with TGFβ1. Images of the areas of 2D Fe-IMAC gels with annotation of phosphoprotein spots p72 and p74, in which 14-3-3σ was identified are shown. Values of the protein spot volumes are shown below images of gels for both protein spots. (E) Phosphorylation of endogenous 14-3-3σ in MCF10A cells was evaluated by immunoprecipitation with anti-phosphoserine, threonine and tyrosine antibodies (upper panel) or by incorporation of 32P (middle panel). Control immunoprecipitation of 14-3-3σ is shown in lower panel. Densitometry analysis of the protein immunoblots or 32P incorporation is shown in accompanying graphs. (F) Phosphorylation of Flag-14-3-3σ fusion protein expressed in HEK293T cells was evaluated in the same way as for endogenous protein. The upper panel shows detection of phosphorylation by immunoprecipitation and the middle panel shows incorporation of 32P. The lower panel shows expression of 14-3-3σ. Migration positions of 14-3-3σ are shown by the arrows and treatments with TGFβ1 are indicated. Densitometry analysis of the protein immunoblots is shown in accompanying graphs. Representative experiments out of 3 performed are shown.
Figure 314-3-3σ is phosphorylated at Ser69 and Ser74.
(A) Two-dimensional phosphopeptides mapping showed appearance of 2 phosphopeptides upon TGFβ1 treatment. Migration positions of these phosphopeptides are shown by arrows, as #1 and #2 respectively. (B) Phosphopeptide map of endogenous 14-3-3σ precipitated from MCF10A cells. Treatment with TGFβ1 and directions of electrophoresis and chromatography are indicated. (C) Elution positions of 32P-labled amino acids upon Edman degradation are shown for phosphopeptides #1 and #2, respectively. Corresponding tryptic peptide is aligned below the panels. (D) Phosphopeptide maps of the wild-type and Ser74Ala (S74A), Ser69Ala (S69A) and Ser69, 74Ala (S69, 74A) mutants of 14-3-3σ are shown. Disappearance of the spots corresponding to the migration positions of phosphopeptides #1 and #2 are indicated by the arrows. (E) Ser69 and Ser74 residues are located within N-terminal part of 14-3-3σ in close proximity to CDK binding sequence AASS (residues 57–64) [51] and to the basic cluster in the conserved amphipathic groove, consisting of K49, R56 and R127, and mediating the interaction of 14-3-3 with the phosphoamino acid in its ligands [38]. The image shows the structure of the p53 C-terminus bound to 14-3-3σ [52], PDB entry 3LW1.
Figure 414-3-3σ forms a complex with Smad3.
(A) 14-3-3σ interacts with Smad3 in vitro. The interaction is mediated by the MH1 domain. A diagram of Smad3 with its three domains MH1, linker (L) and MH2 is shown on the top panel. N and C denote the amino and carboxyl termini. The left panel shows co-precipitated 14-3-3σ, the right panels show inputs of 14-3-3σ (upper part) and GST constructs (lower part). (B) Complex formation between Smad3 and 14-3-3σ depends on phosphorylation at Ser69 and Ser74. HEK293T cells were transfected with protein expressing DNA constructs as indicated. Migration position of co-precipitated 14-3-3σ is shown by the arrow. The levels of expression of 14-3-3σ and Smad3 proteins are shown on the lower panels. (C) Treatment of cells with TGFβ1 modulates interaction between endogenous Smad3 and 14-3-3σ in time dependent manner. MCF7 cells were treated with TGFβ at concentration of 5 ng/ml for the indicated times. Cell lysates were immunoprecipitated with anti-14-3-3σ antibody. Anti-Smad3 antibody was used in Western blot analysis. Densitometry analysis of Smad3 immunoblot is shown in the accompanying graph. (D) Co-localization of 14-3-3σ and Smad3 after treatment of the cells with TGFβ at concentration of 5 ng/ml. Images of immunofluorescent staining of the cells overexpressing 14-3-3σ and Smad3 proteins, are shown. The magnified cells and the line traces are shown on the right.
Figure 5Smad3-dependent transcriptional activation is regulated by phosphorylation of 14-3-3σ at Ser69 and Ser74.
(A) CAGA (12)-luc reporter activation upon expression of 14-3-3σ constructs and Smad3, * - p value<0.05 (B) DNA precipitation assay shows the recruitment of Smad3 to the CAGA element in the present of wild-type and mutant 14-3-3σ proteins. Expression controls for Smad3 and 14-3-3σ constructs are shown in two lower panels. Densitometry analysis of the protein precipitation is shown in the accompanying graphs. (C, D) TGFβ dependent and Smad3 governed transcriptional activation of PAI-1 and COL7A1 genes. For gene expression analysis, MCF10A cells were stably transfected with the constructs expressing wild type or mutated 14-3-3σ protein and treated with TGFβ1 at concentration of 5 ng/ml for 12 hours. The data shown correspond to a representative experiment out of three performed. (E) Schematic presentation of the restrictive role of 14-3-3σ phosphorylation on TGFβ1/Smad3-dependent transcription.
Figure 6TGFβ1-dependent 14-3-3σ phosphorylation plays a role in regulation of tumor progenitor population.
(A) The role of TGFβ1-dependent 14-3-3σ phosphorylation on TGFβ1-mediated inhibition of sphere initiating population in MCF7 cells. MCF7 cells were stably transfected with the constructs expressing wild type or mutated 14-3-3σ proteins, along with control vector, and used for sphere formation assays in the presence of TGFβ1 at concentration of 5 ng/ml; * - p-value<0.05. (B) Tumorigenic properties of MCF7 cells stably expressing wild type or mutated 14-3-3σ proteins, along with control vector, were analyzed in vivo using NOD/SCID mouse xenograft model. Each experimental group contained at least five mice. Graph shows tumor volumes at day 21 after cell injection; * - p value<0.05. (C) Analysis of cell apoptosis in the xenograft tumors using TUNEL staining. Cells in at least 3 randomly selected fields of view were counted for each condition; * - p-value<0.05. (D) Representative fluorescent images of CD44 and CD24 co-immunostaining in MCF7 xenograft tumors. The percentage of CD44+/CD24− tumor progenitor cells (outlined in white) was counted in at least 3 randomly selected fields of view for each condition; * - p-value<0.05. Scale bar, 30 µm. (E) Immunofluorescence detection of phosphorylated γ-H2A.X at 4 hours after irradiation. MCF7 cells were stably transfected with the constructs expressing wild type or mutated 14-3-3σ proteins, along with control vector, pre-treated with TGFβ1 at concentration of 5 ng/ml for 12 hours and irradiated with 4 Gy X-ray dose. For quantification, at least 100 cells per condition were counted; * - p-value<0.05. Scale bar, 10 µm. (F) Clonogenic radiation survival assay. MCF7 cells were stably transfected with the constructs expressing wild type or mutated 14-3-3σ proteins, along with control vector, pre-treated with TGFβ1 at concentration of 5 ng/ml for 12 hours and irradiated with 4 Gy X-ray dose; * - p-value<0.05. (G) Flow cytometry analysis of tumor progenitor population using ALDEFLUOR assay. MCF7 cells were stably transfected with constructs expressing wild type or mutated 14-3-3σ proteins, along with control vector, treated with TGFβ1 at concentration of 5 ng/ml for 7 days, irradiated with 4 Gy X-ray dose, and analyzed 3 days later; * - p-value<0.05. Representative experiments out of 3 performed are shown. (H) Western blot analysis of p53 phosphorylation at Ser15 in MCF7 cells stably transfected with constructs expressing wild type or mutated 14-3-3σ proteins, along with control vector, treated with TGFβ1 at concentration of 5 ng/ml for 12 h and irradiated with 4 Gy X-ray dose. The cells were analyzed 4 hours after irradiation. (I) Results of semi-quantitative RT-PCR analysis for p21 gene expression in MCF7 cells stably transfected with DNA constructs encoding wild type or mutated 14-3-3σ proteins, along with control DNA plasmid and treated with TGFβ1 at concentration of 5 ng/ml for 12 h. (J) Treatment of the cells with TGFβ1 modulates interaction between endogenous p53 and 14-3-3σ in time dependent manner. MCF7 cells were treated with TGFβ1 at concentration of 5 ng/ml for the indicated times. Cell lysates were immunoprecipitated with anti-14-3-3σ antibody. Anti-p53 antibody was used for immunoblot analysis. The results of blue native PAGE are shown below.
Figure 7TGFβ1-dependent phosphorylation of 14-3-3σ regulates Smad3 dependent transcription through involvement of p53 in the transcriptional complexes.
(A) Results of the luciferase activity assay using CAGA (12)-luc reporter. Co-expression of p53 had a restrictive effect on Smad3-dependent transcriptional activity in cells not treated with TGFβ, * - p value<0.05. (B) The results of DNA immunoprecipitation analysis. p53 phosphorylated at Ser392 is recruited to the CAGA element in presence of 14-3-3σ and Smad3 in the manner dependent on 14-3-3σ phosphorylation. Densitometry analysis of the p53 precipitation is shown in accompanying graph. (C) Schematic presentation of the role of 14-3-3σ phosphorylation on a functional interaction of TGFβ1/Smad3 and p53/p21 signaling.